“The sale of our Advanced Bioprocessing business will create greater focus for our Life Sciences segment where BD has outstanding opportunities to contribute significant innovation for disease and therapy research and clinical diagnostics,” Patrick Kaltenbach, president of life sciences for BD, said. “BD remains committed to our customers in the clinical, life sciences and industrial segments and will continue to sell all of our media product offerings to these important partners.”
The AB business combines technical services programs with peptones that enhance cell culture formations to improve yield and reduce variability in biopharmaceutical applications, BD said.
“Thermo Fisher has a trusted value proposition for customers who are working in biologic drug development and manufacturing,” Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific, said. “The addition of these new capabilities will complement our bioproduction offering and strengthen our ability to serve this rapidly growing market, from development to large-scale production.”
“We are excited that our Advanced Bioprocessing team will have the opportunity to join a company with deep expertise and a long-standing commitment to supporting biopharmaceutical production. It will create new prospects, building on a 25-year history of ensuring that high-quality biopharmaceuticals get to the market quickly,” Kaltenbach said.
BD’s AB business has annual revenue of approximately $100 million, it said.
The deal is expected to close in the beginning of next year.